Generic Name and Formulations:
Lidocaine HCl (as monohydrate) 0.5mg/device; pwd for intradermal inj.
Marathon Pharmaceuticals, LLC
Indications for ZINGO:
To provide local analgesia prior to venipuncture in adults and children or peripheral IV cannulation in children.
Adults and Children:
<3yrs: not established. ≥3yrs: Use only on intact skin. Apply one 0.5mg dose to the planned procedure site 1–3 mins before needle insertion; may repeat once at new site after initial attempt failed. Multiple administrations to same site: not recommended.
Local anesthetic (amide-type).
Avoid eyes, body orifices, mucous membranes or areas with a compromised skin barrier. Severe hepatic disease or pseudocholinesterase deficiency. Bleeding tendencies or platelet disorders: higher risk of superficial dermal bleeding. Labor & delivery. Pregnancy (Cat.B). Nursing mothers.
Additive effects with other local anesthetics.
Application-site reactions (eg, erythema, petechiae, edema, pruritus), systemic reactions (eg, nausea, vomiting), dizziness.
Single-use device (disposable, needle-free)—12
- McDonald's and the Microbiome: What Effect Does Junk Food Have on Gut Bacteria?
- When the Doctor is Depressed: One Clinician Tells His Story
- Most Distinctive Causes of Death Mapped by U.S. State
- Spice + Statin Likely Culprit in Patient with Acute Hepatitis
- First Non-Surgical Tx for "Double Chin" Gains FDA Approval
- Antiviral May Tighten Blood-Brain Barrier Against Pathogens
- Better Outcomes for HIV Patients Who Start Treatment Early, Says Study
- DOD: Live Anthrax Accidentally Sent to Nine States, South Korea
- New OTC Lightweight Wearable Launched for Chronic Pain Relief
- FDA: Beware of Embolization With Dermal Fillers